Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,685.84
(
0.01%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

n4807g

Send PM Follow Ignore
Followers 42
Posts 33948
Boards Moderated 0
Alias Born 07/08/2003

n4807g

Member Level

Re: Titan V post# 213423

Tuesday, 09/05/2017 7:31:08 AM

Tuesday, September 05, 2017 7:31:08 AM

Post# of 257484

The DSMB (Data Safety Monitoring Board) met on August 28 and recommended lowering the dose to 6.25x104 UCART123 cells per kilogram in both studies and capping cyclophosphamide to a total dose of 4g over 3 days.



An unfortunate event. I think the trial will be allowed to continue with adjustments suggested by the DSMB.

Haven't heard any updates on the ongoing UCART19 trial. I assume they've dosed patients........

JUNO dropped their lead drug due to patient deaths and currently is valued at 4.5 billion.

“A bank would never get away with what the Department of Education is doing.”

Sheila Bair

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today